These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 23773347)

  • 41. [Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].
    Auriche M; Bertrand P; Blay N; Danan G; Hamel JD; Imbs JL; Lagier G; Micaleff A; Moore N; Ollagnier M; Reveilleau-Richard S; Soubrié C; Weber F
    Therapie; 1997; 52(2):123-7. PubMed ID: 9231506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events following immunization: is this time for the use of WHO causality assessment?
    Tafuri S; Gallone MS; Calabrese G; Germinario C
    Expert Rev Vaccines; 2015 May; 14(5):625-7. PubMed ID: 25805053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Impact of a regional pharmacovigilance network on notification of adverse drug reactions: results at 3 years].
    Picard S; Polard E; Oger E; Bellissant E
    Therapie; 2015; 70(3):293-9. PubMed ID: 25534522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting.
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):317-22. PubMed ID: 2272712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
    Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
    Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical assessment of drug safety].
    Imbs JL; Welsch M
    Ann Pharm Fr; 2007 Sep; 65(5):298-302. PubMed ID: 17982376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thoughts on signal detection in pharmacovigilance.
    Shakir SA
    Drug Saf; 2007; 30(7):603-6. PubMed ID: 17604411
    [No Abstract]   [Full Text] [Related]  

  • 49. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [French pharmacovigilance database system: examples of utilisation].
    Moore N; Noblet C; Kreft-Jais C; Lagier G; Ollagnier M; Imbs JL
    Therapie; 1995; 50(6):557-62. PubMed ID: 8745956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The French pharmacovigilance surveys: A French distinctiveness, a real input.
    Abou Taam M; Jacquot B; Ferard C; Thery AC; Mounier C; Grandvuillemin A; Jonville-Béra AP; Perault-Pochat MC;
    Therapie; 2021; 76(5):441-447. PubMed ID: 32553501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.
    Lacroix C; Salvo F; Gras-Champel V; Gautier S; Massy N; Valnet-Rabier MB; Grandvuillemin A; Mounier C; Benkebil M; Pariente A; Jonville-Béra AP; Micallef J;
    Therapie; 2021; 76(4):297-303. PubMed ID: 34059351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study.
    Laroche ML; Perault-Pochat MC; Ingrand I; Merle L; Kreft-Jais C; Castot-Villepelet A; Durrieu G; Gras V; Guy C; Jean-Pastor MJ; Jonville-Béra AP; Merlet-Chicoine I; Miremont-Salamé G; Nourhashemi F; Charmes JP;
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):952-60. PubMed ID: 23794320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting.
    Mascolo A; Scavone C; Sessa M; di Mauro G; Cimmaruta D; Orlando V; Rossi F; Sportiello L; Capuano A
    Pharmacol Res; 2017 Sep; 123():122-129. PubMed ID: 28694146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS).
    Shin JY; Jung SY; Ahn SH; Lee SH; Kim SJ; Seong JM; Chung SY; Park BJ
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1115-22. PubMed ID: 25251052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Regional Centers of Pharmacovigilance: a complementary source of efficiency].
    Mazé F; Bégaud B
    Therapie; 1998; 53(4):397-400. PubMed ID: 9806011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months].
    Castot A; Bidault I; Dahan R; Efthymiou ML
    Therapie; 1993; 48(5):469-74. PubMed ID: 8146827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.